Investigational MS Drug Evobrutinib Has Potential, Study Shows Everyday Health MenuNewslettersSearch Multiple Sclerosis News
Study of the Investigational MS Drug Evobrutinib Has Encouraging Results
Evobrutinib is the first in the BTK inhibitor class of drugs to be evaluated for the treatment of MS. By Brian P. DunleavyApril 26, 2021Everyday Health ArchiveFact-CheckedA new class of drugs for treating MS has shown promise in clinical trials.Canva; Everyday HealthThere may soon be a new class of drugs used for the treatment of relapsing multiple sclerosis (RMS): Bruton’s tyrosine kinase (BTK) inhibitor. Evobrutinib is the first BTK inhibitor to be evaluated for the treatment of MS, although other drugs in the class have been used to treat certain forms of cancer. It’s currently undergoing clinical trials for safety and efficacy, and new results from a phase 2 study were presented on April 18 during the 2021 annual meeting of the American Academy of Neurology (AAN). Earlier results of the study were published in 2019 in the New England Journal of Medicine. Evobrutinib Reduced a Key Biomarker of Nerve Cell Damage and Inflammation
In this newer analysis of the phase 2 trial data, evobrutinib was found to significantly reduce blood neurofilament light chain levels, a key biomarker of nerve cell damage and inflammation in people with RMS, when compared with a placebo. A biomarker is a measurable substance whose presence is indicative of disease, and high levels of neurofilament light chain, a type of protein, in the blood is considered a sign of the nerve cell damage that causes MS and the brain atrophy, or loss of brain volume, that occurs with the disease, according to a study coauthor, Jens Kuhle, MD, PhD, the head of the multiple sclerosis center at the University Hospital Basel in Switzerland. “The data presented at AAN provide key insights into the role evobrutinib may play in modulating the clinical course of MS and further suggest that BTK inhibition with evobrutinib may reduce tissue damage associated with MS,” Dr. Kuhle notes. “The findings from this analysis are encouraging and show a strong potential for evobrutinib in the treatment of people living with MS.” BTK Inhibitors Could Short-Circuit Autoimmune Attack in MS
As the name suggests, the BTK inhibitors are designed to limit production of Bruton’s tyrosine kinase in the body. BTK plays a role in the development of B cells, a type of white blood cell involved in the human immune system. MS is an autoimmune disorder, or one in which the immune system attacks healthy tissues in error, and it’s thought that this new class of drugs could short-circuit this process. Phase 3 Trials Currently Enrolling Participants
Kuhle and his colleagues evaluated the effects of evobrutinib in 166 people with RMS, at a twice-daily dose of 75 milligrams. Those treated with the drug had, on average, about 19 percent lower levels of neurofilament light chain in the blood after 12 weeks and 17 percent lower levels after 24 weeks. This same dose is being used in two phase 3 trials of the drug — nicknamed evolutionRMS 1 and evolutionRMS 2 — which are currently enrolling participants. (Drugs must pass through a minimum of three trial phases before they can be approved for use.) In these studies, the safety and efficacy of evobrutinib will be compared with that of Aubagio (teriflunomide). As encouraging as the study results are so far, “Treating MS patients with BTK inhibitors is currently being studied and, so far, [none of these drugs] have been approved for the treatment of [the condition],” Kuhle cautions. NEWSLETTERS Sign up for our Multiple Sclerosis Newsletter
SubscribeBy subscribing you agree to the Terms of Use and Privacy Policy. The Latest in Multiple Sclerosis
How to Craft a Life s Mission Statement
By Trevis GleasonOctober 21, 2022 Dysarthria When MS Makes It Hard to Speak
By Mona SenOctober 20, 2022 Is That Really How I Walk
By Trevis GleasonOctober 18, 2022 How Do You Know When to Throw in the Towel
By Trevis GleasonOctober 14, 2022 Living With MS What to Know About Neuropathic Pain and How to Manage It
Neuropathic pain is not your average pain. Here’s what to know about this unique type of MS pain and how to find relief.By Kerry WeissOctober 12, 2022 UTIs and MS The Importance of Early Diagnosis and Treatment
If you have multiple sclerosis, you may be prone to frequent urinary tract infections. Besides being painful, UTIs can make MS worse, so it’s important...By Kerry WeissOctober 12, 2022 Why Is Orange the Color of MS
By Trevis GleasonOctober 11, 2022 13 Celebrities Who Have Multiple Sclerosis
Look among the millions of people with multiple sclerosis and you'll find famous faces, too. Learn how some of these celebrities are dealing with MS and...By Regina Boyle WheelerOctober 11, 2022 We All Have Something to Teach Our MS Doctors
By Trevis GleasonOctober 7, 2022 EBV An MS Box I Can Finally Tick
By Trevis GleasonOctober 4, 2022 MORE IN What Top MS Researchers Want You to Know About MS Care and Treatment Right Now
16 Conditions Commonly Mistaken for Multiple Sclerosis
Speaking Multiple Sclerosis A Glossary of Common Terms